Abstract
After administration of various amounts of pralidoxime to rats, the levels in serum, brain and cerebrospinal fluid (CSF) were measured using capillary zone electrophoresis (CZE). The calibration curves were established using spiked samples. The calibration covers the ranges from 0.3 – 200 μg/mL, 0.3 – 7 μg/mL and 0.1 – 7 μg/mL for serum, brain and CSF, respectively. The CZE measurement opens the way to the fast and reliable determination of pyridinium aldoxime concentrations in serum, cerebrospinal fluid and brain, thereby monitoring blood-brain and blood-CSF penetration of pyridinium aldoximetype antidotes clinically used in organophosphate poisoning.
Keywords: CZE, pralidoxime, serum, cerebrospinal fluid (CSF), brain
Medicinal Chemistry
Title: Analysis of Pralidoxime in Serum, Brain and CSF of Rats
Volume: 5 Issue: 3
Author(s): Huba Kalasz, Eva Szoko, Tamas Tabi, Georg A. Petroianu, Dietrich E. Lorke, Abdulrab Omar, Salem Alafifi, Almerri Jasem and Kornelia Tekes
Affiliation:
Keywords: CZE, pralidoxime, serum, cerebrospinal fluid (CSF), brain
Abstract: After administration of various amounts of pralidoxime to rats, the levels in serum, brain and cerebrospinal fluid (CSF) were measured using capillary zone electrophoresis (CZE). The calibration curves were established using spiked samples. The calibration covers the ranges from 0.3 – 200 μg/mL, 0.3 – 7 μg/mL and 0.1 – 7 μg/mL for serum, brain and CSF, respectively. The CZE measurement opens the way to the fast and reliable determination of pyridinium aldoxime concentrations in serum, cerebrospinal fluid and brain, thereby monitoring blood-brain and blood-CSF penetration of pyridinium aldoximetype antidotes clinically used in organophosphate poisoning.
Export Options
About this article
Cite this article as:
Kalasz Huba, Szoko Eva, Tabi Tamas, Petroianu A. Georg, Lorke E. Dietrich, Omar Abdulrab, Alafifi Salem, Jasem Almerri and Tekes Kornelia, Analysis of Pralidoxime in Serum, Brain and CSF of Rats, Medicinal Chemistry 2009; 5 (3) . https://dx.doi.org/10.2174/157340609788185882
DOI https://dx.doi.org/10.2174/157340609788185882 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment
Current Drug Abuse Reviews Review of Evidence and Perspectives of Flavonoids on Metabolic Syndrome and Neurodegenerative Disease
Protein & Peptide Letters Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets Targeting Nicotinic Receptors for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets How Do Periodontal Infections Affect the Onset and Progression of Alzheimer’s Disease?
CNS & Neurological Disorders - Drug Targets A Pulmonary Perspective on GASPIDs: Granule-Associated Serine Peptidases of Immune Defense
Current Respiratory Medicine Reviews Irreversible Inhibition of Serine Proteases – Design and In Vivo Activity of Diaryl α-Aminophosphonate Derivatives
Current Medicinal Chemistry Editorial - Coping with Neuropathic Pain: Do We Need More Selective Analgesic Drugs?
Current Pharmaceutical Design Information-Theoretic Characterization of Brain Registration and Structure- Function Relationships
Neuroscience and Biomedical Engineering (Discontinued) Neuroinflammation and Complexes of 17β -Hydroxysteroid Dehydrogenase type 10 - Amyloid β in Alzheimer's Disease
Current Alzheimer Research Insulin-Degrading Enzyme: A Link Between Alzheimer’s and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Tau PET Distributional Pattern in AD Patients with Visuospatial Dysfunction
Current Alzheimer Research Combination Therapy for Multi-Target Manipulation of Secondary Brain Injury Mechanisms
Current Neuropharmacology Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease
Current Pharmaceutical Design Opioid Receptor Ligands Derived from Food Proteins
Current Pharmaceutical Design Statins and Carotid Intima-Media Thickness Reduction: An Up-to-Date Review
Current Medicinal Chemistry Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Causes of Secretion Retention: Patient Factors, Ventilation, Devices, Drugs
Current Respiratory Medicine Reviews Meet Our Editorial Board Member
Current Neuropharmacology SIRT1 as a Novel Potential Treatment Target for Vascular Aging and Age-Related Vascular Diseases
Current Molecular Medicine